While a number of companies are pursuing genetic approaches to cure sickle cell disease, Global Blood Therapeutics, Inc., which has one of the two drugs approved for the hereditary blood disorder in Oxbryta, is focusing on improving treatment and has bagged two early-stage programs from Sanofi.
GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal
Pact Could Be Worth $353m
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
More from Blood and Clotting
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.
• By
With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.
• By
Hematologists’ concerns about hepatoxicity with hemophilia A gene therapies may limit use, but Phase III data for Pfizer’s candidate at ASH show a lower rate of ALT increases than seen with BioMarin’s Roctavian.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.